| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Atea Pharmaceuticals Inc. | AT-752 - (DEFEND-2) | Dengue | Phase 2 | Data Released | Oral | N/A |
| Athersys Inc. | Multistem | Acute myocardial infarction | Phase 2 | Intravenous | Cardiology | |
| Athersys Inc. | MultiStem - (MACOVIA) | COVID-19 induced Acute respiratory distress syndrome (ARDS) | Phase 2/3 | Intravenous | Respiratory | |
| Athersys Inc. | Multistem - (ONE-BRIDGE) | Acute Respiratory Distress Syndrome | NDA Filing | Intravenous | Respiratory | |
| Athersys Inc. | MultiStem - (TREASURE) | Ischemic stroke | Phase 2/3 | Intravenous | Neurology | |
| Athersys Inc. | Multistem - (MASTERS-2) | Ischemic stroke | Phase 3 | Intravenous | Neurology | |
| Athersys Inc. | MultiStem | Trauma patients following hospitalization | Phase 2 | Intravenous | N/A | |
| Athersys Inc. | Multistem - (MASTERS-2) | Ischemic stroke | Phase 3 | Intravenous | Neurology |